Durham, NC, May 9, 2022 – BioAgilytix Labs, LLC (BioAgilytix), a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development, has appointed top healthcare executive David King to its Board of Directors.
Mr. King brings with him more than 20 years of leadership and operational experience in the life sciences and healthcare sectors. He joins BioAgilytix as the CRO embarks on a major expansion of its services including the creation of hundreds of new scientific roles across the company.
Mr. King is the former Executive Chairman and CEO of Laboratory Corporation of America Holdings (Labcorp). King led Labcorp’s transformation from a pure-play US testing laboratory into a leading global life sciences company.
During Mr. King’s tenure, Labcorp established itself as a market leader in laboratory testing and global drug development. He also guided the corporation through 10 years of substantial M&A activity and major changes in Government healthcare reimbursement policy. One of those transactions was a $6 billion acquisition of contract research business Covance Inc. in 2015, which significantly increased Labcorp’s revenue and global presence.
“I’m thrilled to join BioAgilytix at such an exciting juncture in its journey. I very much look forward to working with the Board and the great BioAgilytix team to build on the organization’s impressive track record of success,” said King.
Jim Datin, President and Chief Executive Officer at BioAgilytix, added, “We are delighted to welcome David on board as we embark on a new phase of growth for BioAgilytix. David is a seasoned industry expert in the life sciences sector who will help us navigate our transformational phase to become the market leader for Bioanalytical testing. His wealth of experience and extensive network will be invaluable to the Board as we evolve. I look forward to working closely with David, and the rest of the Board.”
King currently serves on several professional Boards, including Privia Health, ZimVie and VaxCare. His volunteer Board involvement includes Novant Health, PATH and the Emily Krzyzewski Center.
A graduate of Princeton University and the University of Pennsylvania Law School, King started his professional career as a history teacher. After his time as a practicing attorney, including a stint as an assistant U.S. attorney for the District of Maryland, he joined Labcorp as general counsel and chief compliance officer in 2001, then served in roles of increasing responsibility until his retirement in 2020.
This year, the Triangle Business Journal will profile King as one of its 2022 Healthcare Leadership Awards Lifetime Achievement Winner in Life Sciences. He will be honored at a luncheon event at the Umstead Hotel and Spa in Cary on May 19.
BioAgilytix is a leading global contract research organization focused on supporting pharmaceutical and biotech partners in all phases of drug development. With laboratory locations in North Carolina’s Research Triangle Park; Cambridge, Massachusetts; San Diego, California; Melbourne and Brisbane, Australia and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of therapeutics across several industries and disease states.
BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.) BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory.
BioAgilytix’s team of highly experienced scientific and QA professionals ensures high-quality science, data integrity and regulatory compliance through all phases of clinical development. BioAgilytix is a trusted partner to many top global pharmaceutical and biotech companies. For more information, visit bioagilytix.com.